Schantz SP - Search Results

1

An immunologic profile of young adults with head and neck cancer.

Schantz SP, Liu FJ. Schantz SP, et al. Cancer. 1989 Sep 15;64(6):1232-7. doi: 10.1002/1097-0142(19890915)64:6<1232::aid-cncr2820640612>3.0.co;2-u. Cancer. 1989. PMID: 2569924

2

Anticlastogenic effects of 13-cis-retinoic acid in vitro.

Trizna Z, Hsu TC, Schantz SP, Lee JJ, Hong WK. Trizna Z, et al. Among authors: schantz sp. Eur J Cancer. 1992;29A(1):137-40. doi: 10.1016/0959-8049(93)90592-4. Eur J Cancer. 1992. PMID: 1280151

3

Acute-phase proteins in patients with head and neck cancer treated with interleukin 2/interferon alfa.

Clayman GL, Liu FJ, Savage HE, Taylor DL, Lavedan P, Buchsbaum RM, Pellegrino C, Trujillo JM, Young G, Schantz SP. Clayman GL, et al. Among authors: schantz sp. Arch Otolaryngol Head Neck Surg. 1992 Jan;118(1):41-8. doi: 10.1001/archotol.1992.01880010045014. Arch Otolaryngol Head Neck Surg. 1992. PMID: 1370199

4

Protective effects of vitamin E against bleomycin-induced genotoxicity in head and neck cancer patients in vitro.

Trizna Z, Hsu TC, Schantz SP. Trizna Z, et al. Among authors: schantz sp. Anticancer Res. 1992 Mar-Apr;12(2):325-7. Anticancer Res. 1992. PMID: 1374597

5

Hereditary and environmental factors associated with risk and progression of head and neck cancer.

Trizna Z, Schantz SP. Trizna Z, et al. Among authors: schantz sp. Otolaryngol Clin North Am. 1992 Oct;25(5):1089-103. Otolaryngol Clin North Am. 1992. PMID: 1408193 Review.

6

A phase II study of interleukin-2 and interferon-alpha in head and neck cancer.

Schantz SP, Dimery I, Lippman SM, Clayman GL, Pellegrino C, Morice R. Schantz SP, et al. Invest New Drugs. 1992 Aug;10(3):217-23. doi: 10.1007/BF00877250. Invest New Drugs. 1992. PMID: 1428731 Clinical Trial.

7

Detection of regulatory factors of lymphokine-activated killer cell activity in head and neck cancer patients treated with interleukin-2 and interferon alpha.

Clayman GL, Young G, Taylor DL, Savage HE, Lavedan P, Schantz SP. Clayman GL, et al. Among authors: schantz sp. Ann Otol Rhinol Laryngol. 1992 Nov;101(11):909-15. doi: 10.1177/000348949210101105. Ann Otol Rhinol Laryngol. 1992. PMID: 1444098 Clinical Trial.

8

Mutagen sensitivity in patients with head and neck cancers: a biologic marker for risk of multiple primary malignancies.

Schantz SP, Spitz MR, Hsu TC. Schantz SP, et al. J Natl Cancer Inst. 1990 Nov 21;82(22):1773-5. doi: 10.1093/jnci/82.22.1773. J Natl Cancer Inst. 1990. PMID: 1700135 Clinical Trial.

9

Immunomodulation of the induction phase of lymphokine-activated killer activity by acute phase proteins.

Clayman GL, Liu FJ, Taylor DL, Savage HE, Lavedan P, Buchsbaum RM, Trujillo JM, Schantz SP. Clayman GL, et al. Among authors: schantz sp. Otolaryngol Head Neck Surg. 1991 Jul;105(1):26-34. doi: 10.1177/019459989110500104. Otolaryngol Head Neck Surg. 1991. PMID: 1715542

10

Effects of N-acetyl-L-cysteine and ascorbic acid on mutagen-induced chromosomal sensitivity in patients with head and neck cancers.

Trizna Z, Schantz SP, Hsu TC. Trizna Z, et al. Among authors: schantz sp. Am J Surg. 1991 Oct;162(4):294-8. doi: 10.1016/0002-9610(91)90134-y. Am J Surg. 1991. PMID: 1719835

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

216 results

Search Page

Filters